Throughout the congress, HTL Biotechnology’s projects and expertise were showcased through several key moments, including the Biopolymers Portfolio Symposium, the HA Roundtable hosted by La Tribune, the Innovation Tank, and numerous interactions at the HTL booth.
These highlights reflected the richness, diversity, and scientific excellence of HTL’s biopolymer portfolio, as well as the company’s ability to support its partners with innovative and reliable solutions.
IMCAS 2026 once again confirmed the central role of collaboration between industry experts, physicians, and partners in shaping the future of regenerative medicine.
HTL Biotechnology is proud of its teams, grateful for the trust of its clients and partners, and fully committed to pursuing its mission: to push the boundaries of science and contribute to the development of next-generation regenerative solutions.
HTL Biotechnology is recognized for the second consecutive year among France’s most dynamic and innovative mid-sized companies.
On October 28, 2025, HTL Biotechnology hosted its first-ever webinar, “Shaping the Future of Aesthetic Medicine with Premium Biopolymers,” a key initiative to strengthen our presence in Asia and promote the “Feel the Difference with HTL Inside” positioning among major players in aesthetic medicine.
This October, HTL Biotechnology turned pink to support breast cancer prevention.